Document:

EX-10.1

 Exhibit 10.1 

ACKNOWLEDGEMENT OF AMENDMENT 

TO SERVICES AND INVESTMENT AGREEMENT 

THIS ACKNOWLEDGEMENT OF AMENDMENT (this “Acknowledgement”), dated as of May 26, 2015 and effective as of March 31,
2015, is made by and between, EXCO Resources, Inc., a Texas corporation (“EXCO”), and Energy Strategic Advisory Services LLC, a Delaware limited liability company (“ESAS”). EXCO and ESAS are each individually a
“Party” and, collectively, the “Parties”. 
 Reference is hereby made to that certain Services and
Investment Agreement, dated March 31, 2015, by and between the EXCO and ESAS (the “Agreement”). Capitalized terms used herein without definition shall have the meanings given to them in the Agreement. 

WHEREAS, on May 15, 2015, the Parties identified clerical errors related to cross references contained in Sections 6.4(c) and 6.5(e) of
the Agreement; 
 WHEREAS, as a result of the identification of such clerical errors, the Parties now seek to (i) acknowledge that the
current language of Sections 6.4(c) and 6.5(e) does not accurately reflect the original intent of the Parties as of the Execution Date, and (ii) agree upon certain revisions to Sections 6.4(c) and 6.5(e) of the Agreement to properly reflect the
intent of the Parties. 
 NOW, THEREFORE, pursuant to Section 11.10 of the Agreement, the Parties hereto hereby agree to and
acknowledge the following, effective as of the Execution Date: 
  

	 	1.	Section 6.4(c) of the Agreement is hereby amended to replace the reference to “Section 6.1” with “Section 6.2(a) and Section 6.2(b)”. 

 

	 	2.	Section 6.5(e) of the Agreement is hereby amended to replace the reference to “Section 6.2” with “Section 6.1(a) and Section 6.1(b)”. 

 

	 	3.	The enforcement and interpretation of this Acknowledgement shall be governed by the laws of the State of Texas. This Acknowledgement may be executed in multiple counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Facsimile, .pdf or other electronic transmission of copies of signatures shall constitute original signatures for all purposes of this Acknowledgement and any enforcement
hereof. 

 [Remainder of Page Intentionally Left Blank. Signature Pages to Follow] 

 IN WITNESS WHEREOF, the parties have executed this Acknowledgement as of the date first above
written. 
  

			
	ENERGY STRATEGIC ADVISORY SERVICES LLC
		
	Name:		 /s/ Charles John Wilder, Jr.

	By:		Charles John Wilder, Jr.
	Title:		Executive Chairman

 Signature Page to the Acknowledgement 

 
			
	EXCO RESOURCES, INC.
		
	Name:		 /s/ Harold L. Hickey

	By:		Harold L. Hickey
	Title:		President and Chief Executive Officer

 Signature Page to the AcknowledgementEx 4.1 1st Amendment to warrant

FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK
This First Amendment to Warrant to Purchase Stock (this “Amendment”) is dated as of May 29, 2015 by and between COMERICA VENTURES INCORPORATED, successor by assignment to Comerica Bank (the “Holder”) and ROKA BIOSCIENCE, INC., a Delaware corporation (“Company”).    
Recitals.
WHEREAS, Company issued to Comerica Bank that certain Warrant to Purchase Stock dated as of November 21, 2013 (the “Warrant”).  The Warrant was subsequently assigned by Comerica Bank to Holder.  
WHEREAS, pursuant to the Warrant, Comerica Bank was entitled to purchase shares of Series E Preferred Stock.
WHEREAS, in connection with Company’s initial public offering effective July 22, 2014, all shares of the Company’s Series E Preferred Stock converted to shares of the Company’s common stock.
WHEREAS, pursuant to Section 4.6 of the Warrant, any term thereof may be changed by an instrument in writing signed by the party against which enforcement of such change is sought.
WHEREAS, in connection with that certain First Amendment to Loan and Security Agreement dated on or about the date hereof by and between the Company and Comerica Bank, Company and Holder wish to amend the Warrant in accordance with the terms hereof.  
Now, therefore, Company and Holder agree as follows:
1.The Warrant is hereby amended to change the Warrant Price and make other changes such that the caption on the face page of the Warrant reads in full as follows:
	
		
	Corporation:
	ROKA BIOSCIENCE, INC., a Delaware corporation

	Number of Shares:
	10,656

	Class of Stock:
	Common Stock

	Warrant Price:
	$2.87 per share  

	Issue Date:
	November 21, 2013

	Expiration Date:
	November 21, 2023 (Subject to Section 4.1)

2.Company represents and warrants to Holder that the Warrant Price set forth in Section 1 of this Amendment is equal to the average closing price of a share of Company’s common stock reported on a nationally- recognized securities exchange, inter-dealer quotation system or over-the-counter market over the last ten (10) Business Days immediately prior to the date of this Amendment.    

3.Unless otherwise defined herein, all capitalized terms in this Amendment shall be as defined in the Warrant.  The Warrant, as amended hereby, shall be and remain in full force and effect in accordance with its terms and hereby is ratified and confirmed in all respects.  Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Holder under the Warrant, as in effect prior to the date hereof.  The Company represents and warrants that the representations and warranties contained in the Warrant, as amended hereby, are true and correct as of the date of this Amendment.  

4.This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

[signature page follows]

In Witness Whereof, the undersigned have executed this Amendment as of the first date above written.

	
			
	 
	 
	ROKA BIOSCIENCE, INC.

	 
	 
	 

	 
	 
	 

	 
	By:
	/s/ Steven T. Sobieski

	 
	Name:
	Steven T. Sobieski

	 
	Title:
	Senior Vice President and Chief Financial Officer

	 
	 
	 

	 
	 
	 

	 
	 
	COMERICA VENTURES INCORPORATED

	 
	 
	 

	 
	 
	 

	 
	By:
	/s/ LaReeda Rentie

	 
	Name:
	LaReeda Rentie

	 
	Title:
	AVPEx 4.2 May 2015 Warrant

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

WARRANT TO PURCHASE STOCK
	
		
	Corporation:
	ROKA BIOSCIENCE, INC., a Delaware corporation

	Number of Shares:
	52,265  

	Class of Stock:
	Common Stock 

	Warrant Price:
	$2.87 per share  

	Issue Date:
	May 29, 2015

	Expiration Date:
	May 29, 2025 (Subject to Section 4.1)

THIS WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable consideration, the receipt of which is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the “Shares”) of ROKA BIOSCIENCE, INC. (the “Company”) at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.
ARTICLE 1
EXERCISE

1.1     Method of Exercise.  Holder may exercise this Warrant by a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the Company (or such other appropriate location as Holder is so instructed by the Company). Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

1.2     [Reserved]. 

1.3     Delivery of Certificate and New Warrant.  Within 30 days after Holder exercises this Warrant and the Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired.

1.4    Replacement of Warrants.  In the case of loss, theft or destruction of this Warrant, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.   

1.5     Acquisition of the Company.

1.5.1    “Acquisition.”  For the purpose of this Warrant, “Acquisition” means (a) any sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger, sale of the voting securities of the Company or other transaction or series of related transactions where the holders of the Company’s securities before the transaction or series of related transactions beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction or series of related transactions.

1.5.2      Treatment of Warrant in the Event of an Acquisition.  The Company shall give Holder written notice at least 15 days prior to the closing of any proposed Acquisition.  The Company will use commercially reasonable efforts to cause (i) the acquirer of the Company, (ii) successor or surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume this Warrant as a part of the Acquisition.
(a)    If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the  unexercised portion of 

this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing.  The Warrant Price shall be adjusted accordingly, and the Warrant Price and number and class of Shares shall continue to be subject to adjustment from time to time in accordance with the provisions hereof.
(b)    If the Acquirer refuses to assume (i) this Warrant (ii) all other warrants of the Company and (iii) employee or other options of the Company, then in connection with the Acquisition, the Company shall give Holder an additional written notice at least ten (10) days prior to the closing of the Acquisition of such fact.  In such event, notwithstanding any other provision of this Warrant to the contrary, Holder may immediately exercise this Warrant in the manner specified in this Warrant with such exercise effective immediately prior to closing of the Acquisition.  If Holder elects not to exercise this Warrant, then this Warrant will terminate immediately prior to the closing of the Acquisition.  Notwithstanding any other provision of this Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection with an Excluded Acquisition (as defined below), then effective as of the date that is ten (10) days prior to the closing of such Acquisition, the Holder shall have the option to elect that the Warrant Price be adjusted, without further action of any party, to be fifty percent (50%) of the fair market value of the Warrant Shares (or such lesser amount as is actually received in value per share of the Acquirer in exchange for the Warrant Shares).  As used herein, an “Excluded Acquisition” means, an Acquisition where the consideration that the holders of the Shares are entitled to receive on account of the Shares consists entirely of cash and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the closing of such Acquisition may be publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or an effective registration statement under the Act.  In the event the Acquirer has assumed any other warrants of the Company or employee or other options of the Company, then Acquirer shall assume this Warrant.  
  

ARTICLE 2
ADJUSTMENTS TO THE SHARES

2.1     Stock Dividends, Splits, Etc.  If the Company declares or pays a dividend on its common stock payable in common stock, or other securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred.

2.2     Reclassification, Exchange or Substitution.  Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event.  The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property.  The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price, the number of securities or property issuable upon exercise of the new warrant and expiration date.  The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events.  

2.3      Adjustments for Combinations, Etc.  If the outstanding Shares are combined or consolidated, by reclassification, reverse split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased.  If the outstanding Shares are split or multiplied, by reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be proportionately decreased.

2.4    [Reserved].    

2.5      No Impairment.  The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article 2 against impairment.

2.6     Certificate as to Adjustments.  Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based.  The Company shall, upon written request, furnish Holder a 

certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.

2.7      Fractional Shares.  No fractional Shares shall be issuable upon exercise of this Warrant and the Number of Shares to be issued shall be rounded down to the nearest whole Share.  If a fractional share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest by paying Holder an amount in cash computed by multiplying the fractional interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share.

ARTICLE 3
REPRESENTATIONS AND COVENANTS OF THE COMPANY

3.1      Representations and Warranties.  The Company hereby represents and warrants to, and agrees with, the Holder as follows:

3.1.1      The initial Warrant Price referenced on the first page of this Warrant is not greater than the average closing price of a share of Company’s common stock reported on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market over the last ten (10) Business Days immediately prior to the Issue Date

3.1.2      All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

3.1.3      As of March 31, 2015, the Company had: (i) 18,046,618 shares of Common Stock outstanding; (ii) 1,179,350 shares underlying outstanding options; (iii) 270,813 shares underlying outstanding warrants; and (iv) 829,090 shares available for future issuance under its equity compensation plan.  

3.2  Notice of Certain Events.  If the Company proposes at any time (a) to declare any dividend or distribution upon its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) to effect any reclassification or recapitalization of stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (1) at least 20 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and (2) in the case of the matters referred to in (c) and (d) above at least 20 days prior written notice of the date when the same will take place (and specifying the date on which the holders of stock will be entitled to exchange their stock for securities or other property deliverable upon the occurrence of such event).  Upon request, the Company shall provide Holder with such information reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant Shares in the case of matters referred to (a), (b), (c) and (d) herein above.

3.3      Information Rights.  

3.1.1    So long as the Holder holds this Warrant and/or any of the Shares and Company has not furnished to Holder and/or filed the same pursuant to Section 3.1.2, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communications,  information and/or communiqués to the shareholders of the Company, (b) within one hundred eighty (180) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements.  In addition, and without limiting the generality of the foregoing, so long as the Holder holds this Warrant and/or any of the Shares, the Company shall afford to the Holder the same access to information concerning the Company and its business and financial condition as would be afforded to a holder of the class of Shares under applicable state law and/or any agreement with any holder of the class of Shares.  Non-compliance with the foregoing shall not constitute a breach of this Warrant provided that the Company complies within a ten (10) business day cure period.  
3.1.2    The Company shall deliver to Holder, in the event that the Company becomes subject to the reporting requirements under the Securities Exchange Act (“SEC”) of 1934, within five (5) days of filing, copies of all periodic and other reports, proxy statements and other materials filed by the Company with the SEC or similarly acting governmental 

agency, any national securities exchange, or distributed to its shareholders, as the case may be.  Documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which the Company posts such documents, or provides a link thereto, on the Company’s website on the Internet at the Company’s website address; provided, however, the Company shall promptly notify Holder in writing (which may be by electronic mail) of the posting of any such documents.  As to any information contained in the materials furnished pursuant to this Section 3.1.2, the Company shall not be required separately to furnish such information under Sections 3.1.1(b)-(c), but the foregoing shall not be in derogation of the obligation of the Company to furnish the information and materials described in such Sections 3.1.1(b)-(c) at the times specified therein.
ARTICLE 4
MISCELLANEOUS
4.1      Term; Exercise Upon Expiration.  This Warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above.  The Company agrees that Holder may terminate this Warrant, upon notice to the Company, at any time in its sole discretion. 

4.2      Legends.  This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form:
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF THIS ARTICLE 4, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
4.3      Compliance with Securities Laws on Transfer.  This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee.  The Company shall not require Comerica Bank (“Bank”) or a Bank Affiliate (as defined herein) to provide an opinion of counsel or investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated (“Comerica”), or any other affiliate of Bank (“Bank Affiliate”); provided, that the Company is provided with documentation, reasonably acceptable to the Company, evidencing that such transferee is an affiliate of the Bank and that such transfer is being made without consideration.

4.4      Transfer Procedure.  After receipt of the executed Warrant, Bank will transfer all of this Warrant to Comerica Ventures Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”).  Subject to the provisions of Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of this Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that Holder may transfer all or part of this Warrant to its affiliates, including, without limitation, Ventures, at any time without notice or the delivery of any other instrument to the Company, and such affiliate shall then be entitled to all the rights of Holder under this Warrant and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant is issued in the name of the affiliate that exercises this Warrant.  The terms and conditions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns.

4.5      Notices.  All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a nationally recognized overnight courier service (such as, but not limited to, Federal Express, DHL or UPS), fee prepaid, or on the first business day after transmission by facsimile, at such address or facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time.  Effective upon the receipt of executed Warrant and initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:

Comerica Ventures Incorporated
Attn:  Warrant Administrator
1717 Main Street, 5th Floor, MC 6406
Dallas, Texas 75201

Facsimile No. (214) 462-4459
All notices to the Company shall be addressed as follows:
Roka Bioscience, Inc.
Attn: Steven T. Sobieski, Sr.
20 Independence Blvd., 4th Floor
Warren, NJ 07059
Facsimile No. (908) 604-2008

4.6      Amendments; Waiver.  This Warrant and any term hereof may be amended, changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such amendment, change, waiver, discharge or termination is sought.

4.7      Attorneys’ Fees.  In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

4.8    Governing Law.  This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to its principles regarding conflicts of law.

[Remainder of page left intentionally blank.  Signature page to follow.]

	
		
	ROKA BIOSCIENCE, INC.

	 
	 

	By:
	/s/ Steven T. Sobieski

	Name:
	Steven T. Sobieski

	Title:
	Senior Vice President and Chief Financial Officer

	 
	 

                    

[SIGNATURE PAGE TO WARRANT TO PURCHASE STOCK]    
    

APPENDIX I
NOTICE OF EXERCISE
1.    The undersigned hereby elects to purchase ______________ shares of the ______________ stock of Roka Bioscience, Inc. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full.
2.    Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:
Comerica Ventures Incorporated
Attn:  Warrant Administrator
1717 Main Street, 5th Floor, MC 6406
Dallas, Texas 75201
Facsimile No. (214) 462-4459
3.    The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.
    	
	
	COMERICA VENTURES INCORPORATED or Assignee

	 

	 

	(Signature)

	 

	 

	(Name and Title)

	 

	 

	(Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]